DNA repair capacity in circulating lymphocytes and influence on platinum effect in tumor cells

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1567-1568

  Olaussen, Ken André ^a   André, Fabrice ^a   Soria, Jean Charles ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BRCA1 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; PROTEIN P53; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; DNA REPAIR; DRUG EFFECT; DRUG EFFICACY; HUMAN; JAPANESE; LETTER; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELIABILITY; REPORTER GENE; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL; FEMALE; GENETICS; LUNG TUMOR; LYMPHOCYTE; MALE; METABOLISM; MORTALITY; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE;

EID: 84863002087     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.9888     Document Type: Letter

References (3)

1. Wang LE, Yin M, Dong Q, et al: DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 29:4121-4128, 2011
2. Shiraishi K, Kohno T, Tanai C, et al: Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28:4945-4952, 2011
3. Husain A, He G, Venkatraman ES, et al: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58:1120-1123, 1998 (Pubitemid 28183195)